Sunesis Pharmaceuticals Inc (SNSS) saw its loss narrow to $9.83 million, or $0.47 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $10.09 million, or $0.70 a share. Revenue during the quarter grew 4.53 percent to $0.67 million from $0.64 million in the previous year period.
Operating loss for the quarter was $9.44 million, compared with an operating loss of $9.86 million in the previous year period.
“Following recent regulatory developments, our reversible non-covalent BTK inhibitor, SNS-062, is the central focus of our development efforts and resources,” said Daniel Swisher, president and chief executive officer of Sunesis. “Data from SNS-062’s preclinical and healthy volunteer studies suggest a unique drug profile for this next-generation BTK inhibitor and the potential to overcome the key resistance mechanism of ibrutinib. SNS-062 has the potential to address this increasingly well-defined and prevalent unmet need in CLL and other B-cell malignancy patients with C481S mutations, and we look forward to dosing the first patient in our Phase 1B/2 study this quarter.”
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]
